74786-02-0

Basic information

• Product Name: [[1-(tert-butoxy)ethenyl]oxy](tert-butyl)dimethylsilane
• Synonyms: (1-tert-Butoxyvinyloxy)(tert-butyl)dimethylsilane;[[1-(tert-butoxy)ethenyl]oxy](tert-butyl)dimethylsilane;Silane, [[1-(1,1-dimethylethoxy)ethenyl]oxy](1,1-dimethylethyl)dimethyl-
• CAS NO: 74786-02-0
• Molecular Formula: C₁₂H₂₆O₂Si
• Molecular Weight: 230.41914
• Mol File: 74786-02-0.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 224℃
• Flash Point: 75℃
• Appearance: /
• Density: 0.853
• CAS DataBase Reference: [[1-(tert-butoxy)ethenyl]oxy](tert-butyl)dimethylsilane(CAS DataBase Reference)
• NIST Chemistry Reference: [[1-(tert-butoxy)ethenyl]oxy](tert-butyl)dimethylsilane(74786-02-0)
• EPA Substance Registry System: [[1-(tert-butoxy)ethenyl]oxy](tert-butyl)dimethylsilane(74786-02-0)

Safety Data

• Hazardous Substances Data: 74786-02-0(Hazardous Substances Data)

Usage

General Description

[1-(tert-butoxy)ethenyl]oxy](tert-butyl)dimethylsilane is a complex chemical compound with a formula of C10H22O2Si. It contains two tert-butyl groups, two methyl groups, and an ethenyl oxy group attached to a silicon atom. The compound is commonly used as a reagent in organic synthesis, specifically in cross-coupling reactions. It is also used as a building block in the production of advanced materials and pharmaceuticals. The compound's unique structure and functional groups make it useful in a variety of chemical reactions and applications in the fields of chemistry and materials science.

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 540-88-5 acetic acid tert-butyl ester 

Downstream Products

• 102340-98-7 (4SR,5SR)-2,2-dimethyl-4-hydroxy-5-(benzyloxy)heptan-3-one 
• 102285-99-4 tert butyl (3SR,4SR)-3-hydroxy-4-(benzyloxy)pentanoate 
• 102285-93-8 tert butyl (3RS,4SR)-3-hydroxy-4-(benzyloxy)pentanoate 
• 84850-37-3 (3S,4R)-3-Hydroxy-4-methyl-5-phenyl-pentanoic acid tert-butyl ester 
• 84850-37-3 (3R,4R)-3-Hydroxy-4-methyl-5-phenyl-pentanoic acid tert-butyl ester 
• 121614-12-8 tert-butyl (4S)-3--4,5-(isopropylidenedioxy)pentanoate 
• 113778-38-4 (3S^*,5S^*)-3,5-dihydroxy-6-methylheptanoic acid δ-lactone 
• 84850-33-9 (3S,4R)-3-Hydroxy-4-phenyl-pentanoic acid tert-butyl ester 
• 84850-33-9 (3R,4R)-3-Hydroxy-4-phenyl-pentanoic acid tert-butyl ester 
• 111524-19-7 tert-butyl (4S,5S)-3--4,5-(isopropylidenedioxy)hexanoate 
• 99686-73-4 (R)-6,6-Dimethyl-5-oxo-3-((S)-1-phenyl-ethyl)-heptanoic acid 
• 99686-73-4 (S)-6,6-Dimethyl-5-oxo-3-((S)-1-phenyl-ethyl)-heptanoic acid 
• 111554-02-0 tert-butyl (3S,4S,5S)-3--4,5-(isopropylidenedioxy)hexanoate 
• 111524-22-2 tert-butyl (4S,5S)-3--4,5-(isopropylidenedioxy)hexanoate 

Relevant articles and documents

Diastereoselectivity in the Lewis Acid Mediated Aldol Reaction of Chiral α, β-Epoxyaldehydes with a Ketene Silyl Acetal

The Lewis acid mediated aldol reaction of chiral α, β-cis and trans epoxyaldehydes 1 and 2 with tert-butyl ketene silyl acetal proceeds mainly with anti diastereofacial preference. The best results were obtained for cis epoxyaldehyde 1 in the presence of catalytic amounts of BiCl3 · 1.5 eq. ZnI2 (anti:syn ～ 13:1), whereas the poorest stereoselectivity was observed when an excess of LiClO4 was used (anti:syn ～ 1:1). The more stable epoxyaldehyde conformers were determined and the diastereofacial preference was found to be in agreement with a nucleophilic attack on the energetically more favoured conformers.

CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.

CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody consisting of the Trastuzumab, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.